For example, it is known that simultaneous knockdown of B-cell lymphoma (Bcl) 2 and RIG-I-dependent IFN-induction is superior to either therapy alone in an in vivo melanoma mouse model [198]. The gene discussed is IFNA1; the disease is melanoma.